Routine delivery footage you already capture.
Mapping precision, smoothness, instability, and tremor.
A sponsor-facing read, aligned to your procedural and clinical endpoints.
DexteraAI's initial focus is retinal gene and cell therapy programs requiring subretinal delivery. These trials involve high-value biologic products, technically demanding surgical administration, and narrow regulatory and adoption pathways because established intravitreal therapies already exist for major retinal diseases.
Four applications spanning pre-pivotal analysis through post-market surgeon quality assurance.
Evaluate whether delivery-performance metrics are associated with sponsor-defined procedural, safety, imaging, or clinical endpoints.
Track whether technical-performance profiles remain stable across surgeons, sites, cases, and time.
Assess whether surgical technical variability may have contributed to efficacy, safety, or durability variability.
Support objective, video-derived feedback for surgeon onboarding, credentialing, retraining, and post-market monitoring.
If you're developing a subretinal therapy and thinking about surgical variability, we'd like to hear about it.